PharVision Advisers’s TransAlta TAC Stock Holding History

PharVision Advisers’s Portfolio TAC Stock Details TAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-35,899	Closed	-$454K	–	582
2025 Q4	$454K	Buy	+35,899	New	+$536K	0.23%	69

Other funds holding TAC

Brookfield Corp Toronto, Ontario, Canada $77B AUM 10.33% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return

PharVision Advisers's TAC Position: Q1 2026 in Review

PharVision Advisers sold out of TransAlta (TAC) in Q1 2026, closing a stake of 35,899 shares — an estimated $454K sold.

PharVision Advisers first reported a position in TAC in Q4 2025 and held it in 1 quarter. The position peaked at $454K in Q4 2025. 178 funds tracked by Wall St. Rank hold TAC as of Q1 2026.

PharVision Advisers reported no remaining TransAlta position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 35,899 TransAlta shares in Q1 2026, an estimated $454K.
PharVision Advisers first reported a position in TransAlta in Q4 2025 and held it in 1 quarter.
PharVision Advisers's TransAlta position peaked at $454K in Q4 2025.
178 funds tracked by Wall St. Rank held TransAlta as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.